Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Abbott And GSK Join For Cancer Diagnostic
by Rick Mullin
July 20, 2009
| A version of this story appeared in
Volume 87, Issue 29
Abbott Laboratories and GlaxoSmithKline will develop an automated molecular diagnostic test that uses polymerase chain reaction (PCR) technology to screen non-small-cell lung cancer tumors for expression of the MAGE-A3 antigen. MAGE-A3 is a tumor-specific antigen that is expressed in non-small-cell lung cancer and other cancer types. GSK currently has a MAGE-A3 antigen-specific cancer immunology candidate in Phase III development. "Through this partnership, we aim to make MAGE-A3 testing of lung tumors available in standard pathology labs around the world," says Vincent Brichard, head of immunotherapeutics at GSK.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter